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Abstract
Background: A resection with clear margins (R0 resection) is the most important prognostic factor in patients with locally recurrent
rectal cancer (LRRC). However, this is achieved in only 60 per cent of patients. The aim of this study is to investigate whether the ad-
dition of induction chemotherapy to neoadjuvant chemo(re)irradiation improves the R0 resection rate in LRRC.
Methods: This multicentre, international, open-label, phase III, parallel-arms study will enrol 364 patients with resectable LRRC after pre-
vious partial or total mesorectal resection without synchronous distant metastases or recent chemo- and/or radiotherapy treatment.
Patients will be randomized to receive either induction chemotherapy (three 3-week cycles of CAPOX (capecitabine, oxaliplatin), four 2-
week cycles of FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) or FOLFORI (5-fluorouracil, leucovorin, irinotecan)) followed by neoadjuvant
chemoradiotherapy and surgery (experimental arm) or neoadjuvant chemoradiotherapy and surgery alone (control arm). Tumours will
be restaged using MRI and, in the experimental arm, a further cycle of CAPOX or two cycles of FOLFOX/FOLFIRI will be administered before
chemoradiotherapy in case of stable or responsive disease. The radiotherapy dose will be 25  2.0 Gy or 28  1.8 Gy in radiotherapy-naive
patients, and 15 2.0 Gy in previously irradiated patients. The concomitant chemotherapy agent will be capecitabine administered twice
daily at a dose of 825 mg/m2 on radiotherapy days. The primary endpoint of the study is the R0 resection rate. Secondary endpoints are
long-term oncological outcomes, radiological and pathological response, toxicity, postoperative complications, costs, and quality of life.
Discussion: This trial protocol describes the PelvEx II study. PelvEx II, designed as a multicentre, open-label, phase III, parallel-arms
study, is the first randomized study to compare induction chemotherapy followed by neoadjuvant chemo(re)irradiation and surgery
with neoadjuvant chemo(re)irradiation and surgery alone in patients with locally recurrent rectal cancer, with the aim of improving
the number of R0 resections.
Introduction
Locally recurrent rectal cancer (LRRC) occurs in 6–10 per cent of
patients who undergo intentionally curative surgery for primary
rectal cancer1,2. To cure patients with LRRC, achieving a resection
with clear resection margins (R0 resection) is imperative2–8.
When an R0 resection is achieved, 5-year overall survival rates
vary between 48 and 58 per cent, whereas a resection without
clear resection margins (R1/2 resection) results in a 5-year sur-
vival rate of only 10–18 per cent. Moreover, incomplete resections
are associated with 5-year local re-recurrence rates of 70–80 per
cent, and often result in severe morbidity, poor quality of life,
and/or death5,6,9–13. Unfortunately, the attempt to achieve an
R0 resection often fails because of challenging anatomy due to
previous surgery, the presence of fibrosis as a result of previous
radiotherapy, and the involvement of other structures such as
adjacent organs, pelvic sidewall, and sacrum. To increase the
chance of achieving an R0 resection, neoadjuvant treatment with
chemoradiotherapy is considered the standard of care in many
institutions14. In patients who received pelvic radiotherapy previ-
ously, reirradiation with a dose of 30 Gy has been proven to be
safe and effective3,15. Despite the use of neoadjuvant chemo(re)ir-
radiation, R0 resections are achieved in only 60 per cent of
patients16,17. Therefore, there is ongoing research to optimize the
treatment strategy for patients with LRRC.
Potential benefits and disadvantages of induction
chemotherapy
Induction chemotherapy in addition to neoadjuvant
chemo(re)irradiation has the potential to induce more local tu-
mour downstaging than can be achieved with
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chemoradiotherapy alone owing to the supplementary effect of
the induction chemotherapy, and possibly also the synergistic ef-
fect of induction chemotherapy and chemoradiotherapy18.
Improved local downstaging may subsequently increase the R0
resection rate, which has been identified as the main prognostic
factor for overall survival6–8. When local downstaging is excel-
lent, a pathologic complete response (pCR) can be achieved,
which is a predictive variable for survival in patients with LRRC19.
With improved local downstaging, the proportion of patients
with a pCR may also increase. Alongside the local effect, induc-
tion chemotherapy may also have the potential to eradicate
micrometastases20.
The addition of induction chemotherapy also has potential
drawbacks. First, induction chemotherapy is associated with
toxicity21. Second, chemotherapy-induced morbidity could delay,
reduce or prevent subsequent treatment with chemoradiother-
apy and surgery. Third, when chemoradiotherapy is preceded by
induction chemotherapy, the toxicity of chemoradiotherapy may
be increased. Finally, the prolonged and intensified neoadjuvant
course may influence the patient’s performance status and may
have a negative effect on surgical morbidity and mortality rates.
Furthermore, prolonged neoadjuvant treatment may increase
the risk of disease progression and secondary unresectability.
Current evidence
Induction chemotherapy, whether or not combined with neoad-
juvant chemoradiotherapy, is increasingly being used in the
treatment of LRRC, although evidence for this approach is lack-
ing22. Several retrospective studies and phase II clinical trials23–26
performed to investigate the role of induction chemotherapy in
patients with primary locally advanced rectal cancer (LARC) have
reported high R0 resection rates. However, other studies27–29, in-
cluding comparative studies, did not demonstrate superior R0 re-
section rates after the addition of induction chemotherapy to
neoadjuvant treatment.
Several studies investigating this treatment regimen in LARC
used pCR as the primary endpoint. As in the studies focusing on
R0 resection rate, the results were mixed. Some studies described
promising pCR rates, whereas others found no effect of adding in-
duction chemotherapy with regard to the pCR rate30–34.
Regardless of the effect of this treatment on the R0 resection or
pCR rate, induction chemotherapy seemed feasible, with high
rates of compliance with the chemotherapy as well as with the
subsequent chemoradiotherapy, and acceptable toxicity and
postoperative morbidity28,33,35.
The available literature regarding induction chemotherapy in
addition to chemoradiotherapy for patients with LRRC is limited;
currently only three retrospective studies19,36,37 have been pub-
lished. The first study36, which focused on patients with lateral
local recurrence, reported a high R0 resection rate of 85 per cent
in a subgroup of 13 patients who were treated with induction che-
motherapy followed by chemoradiotherapy. In the second and
third studies19,37, 58 and 132 patients respectively underwent in-
duction chemotherapy followed by chemo(re)irradiation. Both
studies reported promising pCR rates of 17 per cent, but the R0 re-
section rates did not appear to have improved. However, in both
studies induction chemotherapy was initially administered to
patients with unresectable disease or prognostically unfavoura-
ble characteristics, which may have had a negative impact on the
R0 resection rate.
Rationale for the study
Although the real benefit provided by the addition of induction
chemotherapy to chemoradiotherapy and surgery for LRRC has
not yet been established, its use is nevertheless increasing22.
This study will randomize patients with LRRC to receive either
induction chemotherapy followed by chemoradiotherapy and
surgery (experimental arm) or chemoradiotherapy and surgery
alone (control arm). As R0 resection is the single most important
prognostic factor for survival in patients with LRRC, the main hy-
pothesis to be tested will be an increase in the R0 resection rate
in the experimental arm compared with the control arm.
Methods
Study design and setting
This is a multicentre, international, open-label, phase III, paral-
lel-arms study that will randomize eligible patients in a 1 : 1 ratio
to receive either induction chemotherapy followed by neoadju-
vant chemoradiotherapy and surgery (experimental arm) or neo-
adjuvant chemoradiotherapy and surgery alone (control arm).
The study is registered with ClinicalTrials.gov (NCT04389086), in-
cluding the list of centres enrolling for the trial. Surgical treat-
ments will be limited to centres that perform at least 10
resections of LRRC per year (expert centres). Induction chemo-
therapy and chemoradiotherapy will be administered in expert
centres and selected non-expert centres. This is protocol version
4.0, dated 10 December 2020.
Participants
Patients aged 18 years or older, with resectable histopathologi-
cally or clinically proven LRRC after previous partial or total mes-
orectal resection, with a WHO performance status of 1 or less will
be eligible for study participation. Patients with distant metasta-
ses at the time of randomization or in the previous 6 months,
those who have undergone chemotherapy and/or radiotherapy in
the past 6 months, patients with any contraindication to chemo-
therapy and/or radiotherapy and/or surgery, and those with con-
current malignancies that interfere with the planned study
treatment or the prognosis of resected LRRC, will be excluded.
Recruitment
Participants will be identified either by physicians in expert
centres, or by physicians in non-expert centres who then refer
the patients to an expert centre. All eligible patients will be
reviewed in a multidisciplinary team (MDT) meeting in an expert
centre to assess whether the patient meets the inclusion and ex-
clusion criteria. The multicentre, international involvement in
this study will ensure adequate participant enrolment to reach
the targeted sample size.
Interventions
Eligible patients who have signed informed consent will be ran-
domized by the coordinating investigator in a 1 : 1 ratio using a
software randomization program (ALEA Clinical; FormsVision,
Abcoude, the Netherlands). Patients will be stratified for previous
chemotherapy, previous radiotherapy, and expert centre. After
randomization, the treating surgical oncologist will refer the pa-
tient to the medical oncologist (experimental arm) or radiation
oncologist (control arm).
The study flow chart is shown in Fig. 1, and study interven-
tions and timelines for patients allocated to the experimental
and control arms in Tables 1 and 2 respectively.









































Years 1–3: 3-monthly CEA, 6-monthly thoracoabdominal CT yearly blood-sample for translational research
Years 4–5: 6-monthly CEA, yearly thoracoabdominal CT-scan












Fig. 1 Study flow chart
B, blood samples for translational research; Q, questionnaires; CEA, carcinoembryonic antigen.
Table 1 Schedule interventions and assessments experimental arm
Before allocation After allocation Follow-up









Thoracoabdominal CT  * † ¶ ††
Pelvic MRI  * †
Questionnaires  #
CEA level ** ¶
Translational research: blood  * ‡ § ††
Translational research: tissue 
Assessments
Baseline characteristics 
Toxicity of induction chemotherapy 
Toxicity of chemoradiotherapy 




Progression-free survival ** ¶
Local recurrence-free survival ** ¶
Disease-free survival ** ¶
Overall survival ** ¶
Quality of life  #
Costs  #
*After three (CAPOX) or four (FOLFOX/FOLFIRI) cycles; †4–6 weeks after finishing chemoradiotherapy; ‡after finishing chemoradiotherapy and before surgery;
§3 months after surgery; ¶6-monthly; #3 and 12 months after surgery; **3-monthly; ††yearly. CEA, carcinoembryonic antigen.
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Induction chemotherapy
Patients allocated to the experimental arm will start treatment
with induction chemotherapy within 4 weeks after randomiza-
tion. Induction chemotherapy will consist of either three 3-week
cycles of CAPOX (oxaliplatin 130 mg per m2 body-surface area
(BSA) intravenously (i.v.) on day 1, capecitabine 1000 mg per m2
BSA, orally, twice daily on days 1–14), four 2-week cycles of
FOLFOX (85 mg per m2 BSA of oxaliplatin i.v. on day 1, 400 mg per
m2 BSA of leucovorin i.v. on day 1, 400 mg per m2 BSA of bolus
5-fluorouracil i.v. on day 1 followed by 2400 mg per m2 BSA of
continuous 5-fluorouracil i.v. on days 1–2), or four 2-week cycles
of FOLFIRI (180 mg per m2 BSA of irinotecan i.v. on day 1, 400 mg
per m2 BSA of leucovorin i.v. on day 1, 400 mg per m2 BSA of bolus
5-fluorouracil i.v. on day 1 followed by 2400 mg per m2 BSA of
continuous 5-fluorouracil i.v. on days 1–2). The choice of chemo-
therapy agent will be left to the physician’s discretion.
After three cycles of CAPOX or four cycles of FOLFOX or
FOLFIRI, pelvic MRI will be performed for local restaging, and
high-dose thoracoabdominal CT for restaging of possible distant
metastases. Restaging imaging will be discussed during a dedi-
cated MDT meeting in one of the expert centres. If a patient
develops distant metastases or local disease becomes unresect-
able, best palliative treatment will be offered according to the
standard of care. If a patient has progressive local disease, but
surgery is still considered feasible, no further systemic therapy
will be administered and patients will start treatment with che-
moradiotherapy. If a patient has stable or responsive disease, in-
duction chemotherapy will be continued with either one 3-week
cycle of CAPOX or two 2-week cycles of FOLFOX or FOLFIRI.
Chemoradiotherapy
Patients in the experimental arm will start chemoradiotherapy
within 3–5 weeks after the first day of the last cycle of chemother-
apy. Patients in the control arm will start chemoradiotherapy
within 4 weeks after randomization. The radiotherapy dose will
depend on whether the patient received radiotherapy previously.
In radiotherapy-naive patients, full-course radiotherapy will con-
sist of 25  2.0 Gy or 28  1.8 Gy radiotherapy. In patients with a
history of radiotherapy, the radiotherapy dose will consist of 15 
2.0 Gy. The target volume will be defined by the gross, clinical,
and planning target volumes (GTV, CTV and PTV respectively),
and will be similar for radiotherapy-naive and previously irradi-
ated patients. The GTV contains all macroscopic visible tumour,
the CTV includes the GTV with a margin of 1 cm, without adjust-
ment of the CTV towards other organs, and the PTV includes
the CTV with a margin that can be determined according to local
policy. Concomitant chemotherapy will comprise capecitabine,
administered orally at a dose of 825 mg/m2 twice daily on radio-
therapy days. In the event of unacceptable toxicity caused by
capecitabine during induction chemotherapy, concomitant tega-
fur/gimeracil/oteracil administered orally at a dose of 25 mg/m2
twice daily on radiotherapy days may be prescribed at the physi-
cian’s discretion.
Restaging
Four to 6 weeks after the last day of radiotherapy, pelvic MRI will
be performed for local restaging and high-dose thoracoabdomi-
nal CT for restaging of possible distant metastases. Restaging im-
aging will be discussed during a dedicated MDT meeting in one of
Table 2 Schedule interventions and assessments control arm
Before allocation After allocation Follow-up









Thoracoabdominal CT  * § **
Pelvic MRI  *
Questionnaires  ¶
CEA level # §
Translational research: blood  † ‡ **
Translational research: tissue  s
Assessments
Baseline characteristics 





Progression-free survival # §
Local recurrence-free survival # §
Disease-free survival # §
Overall survival # §
Quality of life  ¶
Costs  ¶
*4 to 6 weeks after finishing chemoradiotherapy; †after finishing chemoradiotherapy and before surgery; ‡3 months after surgery; §6-monthly; ¶3 and 12 months
after surgery; #3-monthly; **yearly. CEA, carcinoembryonic antigen.











trecht user on 06 August 2021
the expert centres. In the event of distant metastases or unre-
sectable local disease, best palliative treatment will be offered.
Patients with resectable disease will undergo surgery.
Surgery
Surgery will be performed by experienced surgical oncologists
within 10–14 weeks after completion of chemoradiotherapy. The
type of surgery will depend on the location of the recurrence and
involvement of adjacent structures, and will be left to the discre-
tion of the surgeon. When deemed necessary and feasible by the
surgeon and radiation oncologist, intraoperative radiotherapy
may be administered by either intraoperative electron beam ra-
diotherapy or high-dose-rate intraoperative brachytherapy38,39.
Follow-up
Patients will be followed up at 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33,
36, 42, 48, 54, and 60 months after surgery. At each follow-up
point, a blood sample will be taken to determine the level of car-
cinoembryonic antigen (CEA). If the CEA level increases com-
pared with the previous CEA level or the level rises above 5.0 mg/l
during follow-up, high-dose thoracoabdominal CT will be per-
formed. At 6, 12, 18, 24, 30, 36, 48, and 60 months after surgery,
high-dose thoracoabdominal CT will be performed regardless of
the CEA level.
Questionnaires
All participants will be asked to provide separate informed con-
sent to receive validated quality of life questionnaires (European
Organisation for Research and Treatment of Cancer QLQ-C30 and
QLQ-CR29; EuroQol EQ-5D-5LTM (EuroQoL Group, Rotterdam, the
Netherlands)). Patients will receive questionnaires at inclusion,
and 3 and 12 months after surgery either by mail or digitally,
according to their own preference.
Translational research
All participants will be asked to provide separate informed con-
sent for collection of blood samples and/or tumour tissue for fu-
ture translational research. If patients give such consent, an
additional 20 ml blood will be drawn during regular blood draws
before the start of induction chemotherapy (experimental arm
only), before chemoradiotherapy, before surgery, 3 months after
surgery, and once a year during 3 years of follow-up, resulting in
seven samples per patient in the experimental arm and six per
patient in the control arm. Tumour tissue will be collected by the
pathologist, fresh frozen and stored until further use.
Central multidisciplinary team meetings
During the study inclusion period, a monthly central MDT meet-
ing will be organized for quality control. All newly included
patients will be discussed during this meeting, which has been
designed as a teleconference. In addition, eligible patients will be
discussed in the event of uncertainty about whether they meet
the inclusion and/or exclusion criteria. Patients who are under
treatment at the time of the central MDT meeting, or who have
completed treatment, will be discussed only if there are remark-
able findings, such as progression of disease resulting in unre-
sectability.
Outcomes
The primary outcome of the study is the proportion of patients
with a clear resection margin. A resection margin is considered
clear (R0), if there are no tumour cells in any of the resection
surfaces as determined by microscopy (resection margin more
than 0 mm).
Secondary outcomes are:
• 3- and 5-year local re-recurrence-free survival, defined as the
interval between surgery and local re-recurrence;
• 3- and 5-year progression-free survival, defined as the interval
between randomization and progression of local recurrence,
local re-recurrence, distant metastases or death;
• 3- and 5-year metastasis-free survival, defined as the interval
between randomization and development of distant metasta-
ses;
• 3- and 5-year disease-free survival, defined as the interval be-
tween surgery and local re-recurrence, distant metastases or
death;
• 3- and 5-year overall survival, defined as the interval between
randomization and death;
• pathological response, graded according to the Mandard grad-
ing system40;
• radiological response, scored according to the magnetic reso-
nance tumour regression grade (mrTRG);
• compliance rate with induction chemotherapy (i.e., the num-
ber of patients receiving CAPOX, FOLFOX or FOLFIRI as initial
regimen will be tabulated, and dose modification and reason
will be summarized for each regimen);
• toxicity of induction chemotherapy, scored from day 1 of the
first cycle of induction chemotherapy until 1 month after the
final administration, and graded according to the Common
Terminology Criteria for Adverse Events (CTCAE) version 5.0;
• compliance rate with chemoradiotherapy, calculated as the to-
tal radiotherapy dose received divided by the total planned
dose;
• toxicity of chemoradiotherapy, scored from start of radiother-
apy until 3 months after the final dose of radiotherapy, and
graded according to CTCAE version 5.0;
• number of patients undergoing surgery;
• surgical characteristics (e.g., type of resection, ostomy, use of
intraoperative radiotherapy, blood loss, duration of operation,
intraoperative complications);
• major surgical morbidity rate scored from the date of surgery
to 3 months after surgery, and graded according to the
Clavien–Dindo classification41;
• quality of life, assessed with EQ-5D-5LTM, QLQ-C30 and QLQ-
CR29 questionnaires at inclusion, and at 3 and 12 months after
surgery; and
• cost-effectiveness and cost–utility, based on Dutch costing
guidelines for healthcare, the case report forms, and the EQ-
5D-5LTM questionnaire.
Sample size
Currently, an R0 resection is achieved in approximately 60 per
cent of patients undergoing surgery after treatment with neoad-
juvant chemoradiotherapy16,17. However, 25 per cent of patients
who start neoadjuvant chemotherapy are not eligible for surgery
owing to progressive disease: local progression, distant progres-
sion, or death from progression12. This means that an R0 resec-
tion is obtained in only 45 per cent of patients (75 per cent of 60
per cent) who start with intentionally curative treatment. The
study hypothesis is that there will be a 15 per cent increase in the
R0 resection rate (from 45 to 60 per cent) for patients in the exper-
imental arm. A v2 test with a 5 per cent two-sided significance
level indicated that the study would have 80 per cent power to
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detect a significant difference of 15 per cent between the two
groups (given that the percentage in the control group is 45 per
cent) when the sample size in each group is 173 patients. With an
expected dropout of 5 per cent, the total requirement was calcu-
lated as 364 patients.
Statistical methods
Demographics, patient, and tumour characteristics will be pre-
sented for each treatment arm. Continuous data will be reported
as mean (standard deviation) or median (interquartile range or 95
per cent confidence interval), depending on the distribution.
Categorical data will be reported as count with percentage. All
statistical tests will be two-sided and P < 0.050 will be classified
as statistically significant. Patients initially randomized but con-
sidered ineligible afterwards, based on information that should
have been available before randomization, will be excluded from
all analyses.
Analysis of the primary endpoint of this study, the proportion
of patients with an R0 resection, will be based on the intention-
to-treat principle using Fisher’s exact test. In addition, a per-pro-
tocol analysis will be performed as a sensitivity analysis.
All survival curves will be constructed according to the
Kaplan–Meier method, and the log rank test will be used to com-
pare treatment arms, adjusting for stratification factors at ran-
domisation (previous radiotherapy, previous systemic therapy,
and expert centre). In addition, hazard ratios will be calculated
using a Cox proportional hazards regression model, adjusting for
stratification factors. Metastasis-free survival, progression-free
survival, and overall survival will be based on the intention-to-
treat group. Local re-recurrence free survival and disease-free
survival analyses will include only patients who underwent sur-
gery.
Data on surgical characteristics, histopathological characteris-
tics, and major surgical morbidity will be presented by treatment
arm, and will be derived only for patients who underwent sur-
gery. The number of patients undergoing surgery will be analysed
in the intention-to-treat population. Comparison between treat-
ment arms will be done by means of Fisher’s exact test.
The absolute and relative incidence of toxicities related to the
administration of induction chemotherapy or chemoradiother-
apy will be presented by treatment arm, and analysed in all
patients who received at least one dose of neoadjuvant chemo-
therapy (experimental arm) or chemoradiotherapy (control arm).
Comparison between treatment arms will be done by means of
Fisher’s exact test.
Comparison of health-related quality of life between the two
treatment arms at baseline and over time will be performed by
means of a random-effects regression model and will be based on
the intention-to-treat group.
Incremental cost-effectiveness and cost–utility ratios will be
calculated for the extra costs per additional surviving patient and
the extra costs per additional quality-adjusted life year respec-
tively. Non-parametric bootstrapping, drawing samples of the
same size as the original samples and with replacement, will be
applied to generate 95 per cent confidence intervals for (differen-
ces in) costs and health outcomes. Cost-effectiveness planes will
be displayed and cost-effectiveness acceptability curves drawn
for willingness-to-pay values up to e100 000.
Data collection and management
A central study database (Netherlands Comprehensive Cancer
Institute (IKNL), Utrecht, the Netherlands) with an electronic
case report form will be used to record all data required to
address the primary and secondary objectives. Local data man-
agement will be undertaken by the IKNL or an in-hospital quali-
fied local data management team. Questionnaires will be
collected centrally by the coordinating investigators and recorded
using an ISO 27001-certified information security system
(Research Manager, Deventer, Netherlands).
Data safety monitoring board
A central data safety monitoring board (DSMB), consisting of a
medical oncologist, a surgical oncologist, and a statistician, has
been assigned to monitor the safety of study participants, and to
protect the validity and credibility of the study. Members of
the DMSB are independent and have no competing interest. After
100 patients have undergone surgery, the DSMB will review the
safety data. Inclusion will be continued during interim analysis.
At the interim analysis, the number of patients who cannot com-
plete the full course of chemoradiotherapy and the number of
patients with major postoperative morbidity (Clavien–Dindo
grade at least III) will be tabulated and discussed. Examining
these safety and logistical aspects will not affect the total sample
size or the actual a level at final analysis. After the interim analy-
sis, the DSMB will recommend to the trial steering committee
(TSC) whether the study should be continued or terminated.
Should the TSC decide not to fully implement the advice of the
DSMB, it must explain to the medical ethical committee why
(part of) the advice of the DSMB will not be followed.
Harms
All serious adverse events (SAEs) or suspected unexpected seri-
ous adverse events (SUSARs) will be reported by the physician to
the study coordinator within 24 h and without undue delay after
obtaining knowledge of the event. The coordinating investigator
will report SAEs through the web portal ToetsingOnline (https://
www.toetsingonline.nl) to the medical ethical committee that ap-
proved the protocol. The time window for recording SAEs and
SUSARs is from randomization until 3 months after surgery, or
1 month after the last day of neoadjuvant treatment for patients
with progressive disease who did not undergo surgery. SAEs and
SUSARs will be followed up until resolved or until a stable situa-
tion has been reached.
Auditing
The study will be monitored by independent qualified monitors.
The monitoring plan is based on the assessment that the study
carries a moderate risk for the participants.
Research ethics approval
This study was approved by the Medical Research Ethics
Committees United, Nieuwegein, the Netherlands (R20.035), the
Dutch Competent Authority (Centrale Commissie Mensgebonden
Onderzoek, The Hague, the Netherlands; NL73593.100.20), and all
institutional review boards of the participating study centres.
The study will be submitted to the competent authorities, central
ethical committees, and institutional review boards of the partici-
pating international centres.
Protocol amendments
All substantial amendments will be notified to the (principal)
investigators, institutional review boards of all study centres, the
medical ethical committee, the competent authority, and trial
registries.
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Consent and assent
Informed consent will be obtained by the treating physician in
one of the expert centres. Patients will be allowed to provide sep-
arate permission for the collection of blood and/or tissue samples
for translational research, and for receiving quality of life ques-
tionnaires.
Confidentiality
Individual patient information obtained as a result of this study
is considered confidential and its handling will conform with the
Dutch Personal Data Protection Act (AVG). Patients’ confidential-
ity will be ensured by use of study numbers.
Declaration of interests
The investigators declare no financial or other competing
interests.
Access to data
Access to the final data set is reserved for the central data man-
ager, study statistician, coordinating investigator, and trial steer-
ing committee. There are no contractual agreements that limit
this access.
Ancillary and post-study care
The study has no provision for ancillary or post-study care.
Dissemination policy
The results of this study will be dispersed by publishing the
results in international peer-reviewed journals and by offering an
abstract to international (surgical) oncological congresses. Any
publication, abstract or presentation based on patients included
in this study must be approved by the trial steering committee
and coordinating investigator. The principal manuscript resulting
from this study will be published by group authorship (PelvEx
Collaborative).
Discussion
This randomised controlled trial will investigate the role of induc-
tion chemotherapy in patients with LRRC. The results of this
study will demonstrate whether or not induction chemotherapy
has additional value in the treatment of patients with non-me-
tastasized resectable LRRC with regard to the R0 resection rate;
this group of patients has had a poor prognosis so far.
The rationale for R0 resection as the primary outcome in this
study was based on the fact that R0 resection is the most impor-
tant prognostic factor for survival in patients undergoing surgery
for LRRC. Ultimately, an increase in R0 resection rate should lead
to an improvement in local re-recurrence-free and overall sur-
vival. Because of the relatively rarity of LRRC as a result of
improvements in the treatment of primary rectal cancer, and the
fact that approximately 50 per cent of patients with LRRC will not
be eligible for inclusion in this study owing to distant metastases
or unresectable local disease, survival parameters could not be
used as the primary outcome, as power calculations showed that
the sample size would be unfeasible42,43.
The rationale for the induction chemotherapy regimen chosen
in this study is based on studies in (metastatic) colorectal cancer.
In those first-line studies44–47, doublet therapy led to better
response rates and improved survival compared with monother-
apy. Results of triplet therapy among patients with metastatic co-
lorectal cancer have been conflicting48,49. In addition, although
higher response rates have been observed for triple therapy
compared with doublet therapy in patients with right-sided met-
astatic colorectal cancer, this has not been observed in patients
with left-sided disease50,51. Moreover, triplet therapy is associated
with more toxicity, and in patients with LRRC, in particular, toxic-
ity of treatment is considered a major limitation often precluding
curative treatment52. Therefore, doublet therapy is the treatment
regimen of choice. As doublet therapy with capecitabine and
oxaliplatin (CAPOX), 5-fluorouracil, leucovorin, and oxaliplatin
(FOLFOX), and 5-fluorouracil, leucovorin, and irinotecan
(FOLFIRI) have similar efficacy, all are incorporated in the present
study protocol46,53,54.
There are three other ongoing trials investigating the optimal
treatment for patients with LRRC. The French GRECCAR15 study
(Chemotherapy Followed by Pelvic Reirradiation Versus
Chemotherapy Alone as Pre-operative Treatment for Locally
Recurrent Rectal Cancer; NCT03879109) is randomizing between
induction chemotherapy, chemoreirradiation, and surgery versus
induction chemotherapy and surgery in previously irradiated
patients. The primary outcome measure is the R0 resection rate.
The Japanese JCOG1801 study (Surgery Plus Chemo Versus
Chemoradiotherapy Followed by Surgery Plus Chemo for Locally
Recurrent Rectal Cancer; NCT04288999) is randomizing between
surgery followed by adjuvant chemotherapy versus neoadjuvant
chemoradiotherapy, surgery, and adjuvant chemotherapy
(CAPOX/FOLFOX) in radiotherapy-naive patients, with local re-
currence-free survival as the primary outcome measure. The
Chinese NARC study (Efficacy and Safety Study of Neoadjuvant
in Treating Patients With Resectable Local Recurrent Rectal
Cancer; NCT01271192) is randomizing between surgery followed
by adjuvant chemotherapy versus neoadjuvant chemoradiother-
apy, surgery, and adjuvant chemotherapy, with overall survival
as the primary outcome measure. The results of these studies
will be actively monitored to assess whether their results have
any implications for the present study protocol.
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46. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-
Mignard D et al. FOLFIRI followed by FOLFOX6 or the reverse











trecht user on 06 August 2021
sequence in advanced colorectal cancer: a randomized GERCOR
study. J Clin Oncol 2004;22:229–237
47. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of
patients with advanced colorectal cancer improves with the
availability of fluorouracil–leucovorin, irinotecan, and oxalipla-
tin in the course of treatment. J Clin Oncol 2004;22:1209–1214
48. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C et
al. Phase III trial of infusional fluorouracil, leucovorin, oxalipla-
tin, and irinotecan (FOLFOXIRI) compared with infusional fluo-
rouracil, leucovorin, and irinotecan (FOLFIRI) as first-line
treatment for metastatic colorectal cancer: the gruppo oncolo-
gico nor. J Clin Oncol 2007;25:1670–1676
49. Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N,
Athanasiadis A et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxali-
platin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and
irinotecan) as first-line treatment in metastatic colorectal cancer
(MCC): a multicentre randomised phase III trial from the Hellenic
Oncology Research Grooup (HORG). Br J Cancer 2006;94:798–805
50. Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S
et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizu-
mab as first-line treatment of patients with metastatic
colorectal cancer: updated overall survival and molecular sub-
group analyses of the open-label, phase 3 TRIBE study. Lancet
Oncol 2015;16:1306–1315
51. Cremolini C, Antoniotti C, Lonardi S, Bergamo F, Cortesi E,
Tomasello G et al. Primary tumor sidedness and benefit from
FOLFOXIRI plus bevacizumab as initial therapy for metastatic
colorectal cancer. Retrospective analysis of the TRIBE trial by
GONO. Ann Oncol 2018;29:1528–1534
52. Falcone A, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore
L et al. FOLFOXIRI/bevacizumab versus FOLFIRI/bevacizumab as
first-line treatment in unresectable metastatic colorectal cancer
(mCRC) patients: reults of the phase III TRIBE trial by GONO
group. J Clin Oncol 2013;31:3505
53. Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY,
Hochster H et al. Efficacy of oxaliplatin plus capecitabine or infu-
sional fluorouracil/leucovorin in patients with metastatic colo-
rectal cancer: a pooled analysis of randomized trials. J Clin Oncol
2008;26:5910–5917 doi:10.1200/JCO.2008.16.7759
54. Sobrero A, Bennicelli E. Chemotherapy: which drug and when?
Ann Oncol 2010;21:vii130–vii133











trecht user on 06 August 2021
